Reviewing Radius Health Inc. (RDUS)’s and Sesen Bio Inc. (NASDAQ:SESN)’s results

Both Radius Health Inc. (NASDAQ:RDUS) and Sesen Bio Inc. (NASDAQ:SESN) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radius Health Inc. 99.24M 8.61 221.34M -5.57 0.00
Sesen Bio Inc. N/A 0.00 33.69M -0.67 0.00

In table 1 we can see Radius Health Inc. and Sesen Bio Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Radius Health Inc. -223.04% -155% -67.2%
Sesen Bio Inc. 0.00% -85.7% -33.6%

Risk and Volatility

A beta of 0.96 shows that Radius Health Inc. is 4.00% less volatile than Standard and Poor’s 500. Competitively, Sesen Bio Inc.’s beta is 2.08 which is 108.00% more volatile than Standard and Poor’s 500.

Liquidity

The current Quick Ratio of Radius Health Inc. is 5.4 while its Current Ratio is 5.5. Meanwhile, Sesen Bio Inc. has a Current Ratio of 9.1 while its Quick Ratio is 9.1. Sesen Bio Inc. is better positioned to pay off its short-term and long-term debts than Radius Health Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Radius Health Inc. and Sesen Bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Radius Health Inc. 0 1 2 2.67
Sesen Bio Inc. 0 0 0 0.00

The consensus target price of Radius Health Inc. is $43.67, with potential upside of 133.90%.

Insider & Institutional Ownership

Radius Health Inc. and Sesen Bio Inc. has shares held by institutional investors as follows: 0% and 45.2%. Insiders held 0.1% of Radius Health Inc. shares. Competitively, Sesen Bio Inc. has 6.56% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Radius Health Inc. 1.69% 8.98% 26.09% -3.21% -46.96% 20.74%
Sesen Bio Inc. 14.36% 30.32% -43.45% -50.26% 2.59% -33.1%

For the past year Radius Health Inc. has 20.74% stronger performance while Sesen Bio Inc. has -33.1% weaker performance.

Summary

Sesen Bio Inc. beats Radius Health Inc. on 6 of the 10 factors.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.